UBS ALFA Program: What It Pays, What It Locks, and Should You Sign?

The short answer: ALFA, UBS's Aspiring Legacy Financial Advisor program, pays a retiring advisor up to 300% of eligible production to sunset inside the firm, per UBS's own materials. At the top of the band that is competitive with any sunset program in the industry. The cost is structural: a multi-year restricted period, a book that transfers to successor UBS advisors and never leaves the firm, forfeiture economics that make mid-program exit unrealistic, and an open market you are agreeing not to test during the only years it would price you. Sign it for certainty. Do not sign it believing it is a sale, because it is not one.

Every senior UBS advisor gets to this decision eventually, and the firm has made the default path easy to take. Easy is not the same as priced. Here is the program, priced.

What is ALFA, mechanically?

The Aspiring Legacy Financial Advisor program is UBS's retire-in-place offering: the in-house alternative to selling a practice or moving firms before retirement.

The mechanics follow the industry's standard sunset shape. The retiring advisor commits to a transition period during which client relationships move to successor UBS advisors, assists in that handoff, and receives payments over a multi-year schedule that UBS's published materials describe as up to 300% of eligible production. The successors typically fund part of the economics through reduced compensation on the inherited assets, and the retiring advisor takes on the obligations that make the structure work for the firm: stay through the transition, do not compete for or solicit the transitioned relationships afterward.

Add the pieces together and the realistic commitment horizon runs five to seven restricted years across transition and payback. That is not a criticism; it is the design. The firm is buying continuity, and continuity takes years.

What is genuinely good about it?

Three things, honestly stated.

Certainty. No buyer search, no due diligence process, no move. Cerulli's research shows the industry's biggest succession pain point is finding a qualified buyer at all; ALFA deletes that problem.

Continuity for clients. Relationships transfer inside a platform clients already know, with the retiring advisor easing the handoff. For a book of elderly clients or deep multi-generational households, that continuity has real value.

A competitive headline. Up to 300% of eligible production stands alongside Merrill's Client Transition Program and Edward Jones' RTP at the top of the sunset market. UBS is not underpaying relative to its peers; we compare all three in our guide to Edward Jones' RTP.

What does it actually cost?

The costs are structural, and none of them appear in the headline number.

The book never becomes an asset. ALFA consideration is compensation for transition services. You are paid to hand relationships to the firm's chosen successors, inside the firm, on the firm's paper. Contrast the open market: 2025 was a record year for practice sales, with the median RIA changing hands at 11.6 times EBITDA and PE-backed platforms paying 9 to 16 times. A wirehouse advisor cannot sell what they do not own, and signing ALFA is the moment that becomes permanent. The full arithmetic of that difference lives in our retire-in-place versus independence comparison.

The lock is the point. Unpaid tranches are the leash. Leave mid-program and the remaining economics evaporate or reverse; peer-firm litigation over sunset agreements has produced seven-figure judgments against advisors who tried. Assume the door closes at signature.

You are underwriting UBS's next seven years. The restricted period outlasts any single comp plan, leadership team, or strategy. UBS cut sub-$750K producer payouts in 2025, then reversed course for 2026 after watching advisors walk. Whatever you think of those specific choices, they demonstrate the variable you are locking yourself to: firm policy will change during your commitment, and you will have no exit when it does. Our running coverage of that dynamic is in the UBS 2026 departures analysis.

Your successors inherit your constraints. The next generation on your team receives the book with payback obligations attached and their own restrictions layered on. Advisors weighing ALFA on behalf of a team should read the successor-side terms as carefully as their own.

Who should sign it, and who should not?

Sign it if you want zero disruption, your clients are deeply platform-entangled, you have no successor outside the firm and no appetite for a sale process, and you would choose UBS again today for the next seven years. For that advisor, ALFA is a rational, dignified exit, and the certainty is worth real money.

Do not sign it yet if you have never priced the alternative. The move-then-monetize path, transitioning to a model where the practice becomes an owned, sellable asset, produces a fundamentally different lifetime number for many practices, and the difference compounds with book size and remaining runway. The honest comparison requires your production, your client retention profile, and your time horizon, which is exactly the modeling we do, and it must happen before signature, because afterward there is nothing left to compare.

The advisors we have seen regret ALFA almost never regret the check. They regret discovering, in year three of seven, that the check was the last decision they got to make.

If you are holding an ALFA offer or expect one in the next cycle, request an introduction. We will price both paths against your actual book, in writing, and if the sunset genuinely wins for your situation, we will tell you that too.